Source:http://linkedlifedata.com/resource/pubmed/id/11067902
Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions |
umls-concept:C0009013,
umls-concept:C0027651,
umls-concept:C0041361,
umls-concept:C0085358,
umls-concept:C0205169,
umls-concept:C0242633,
umls-concept:C0872192,
umls-concept:C1332717,
umls-concept:C1413244,
umls-concept:C1423842,
umls-concept:C1515655,
umls-concept:C1548602,
umls-concept:C1706438,
umls-concept:C2698600
|
| pubmed:issue |
10
|
| pubmed:dateCreated |
2000-11-21
|
| pubmed:abstractText |
Although CD8(+) T cells play a central role as immune effectors, CD4(+) T cells act to control the activation and persistence of the CD8(+) T cell response in autoimmune disease, antiviral immunity, and experimental systems with immunogenic model tumor Ag. However, little information is available on the effects of CD4(+) T cells on the function of endogenous CD8(+) T lymphocytes recognizing authentic tumor rejection Ag with limited immunogenicity. We report here that the prophylactic or postchallenge administration of T helper Th1-type and Th2-type CD4(+) clones specific for an unmutated rejection Ag (murine P815AB, resembling tumor-specific shared Ag in humans) leads to the induction of P815AB-specific reactivity in vivo and concomitant tumor destruction, with quantitative rather than qualitative differences characterizing the antitumor activity of Th1 vs Th2 cells. Because the transferred CD4(+) cells lacked direct antitumor activity in vitro and required the de novo generation of P815AB-specific CD8(+) T cells in vivo, these findings suggest that CD4(+) lymphocytes can enhance the ability of host APC to initiate an endogenous CD8(+) T cell response to authentic, poorly immunogenic tumor rejection Ag.
|
| pubmed:language |
eng
|
| pubmed:journal | |
| pubmed:citationSubset |
AIM
|
| pubmed:chemical | |
| pubmed:status |
MEDLINE
|
| pubmed:month |
Nov
|
| pubmed:issn |
0022-1767
|
| pubmed:author | |
| pubmed:issnType |
Print
|
| pubmed:day |
15
|
| pubmed:volume |
165
|
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
Y
|
| pubmed:pagination |
5495-501
|
| pubmed:dateRevised |
2006-11-15
|
| pubmed:meshHeading |
pubmed-meshheading:11067902-Amino Acid Sequence,
pubmed-meshheading:11067902-Animals,
pubmed-meshheading:11067902-Antigens, Neoplasm,
pubmed-meshheading:11067902-CD4-Positive T-Lymphocytes,
pubmed-meshheading:11067902-CD8-Positive T-Lymphocytes,
pubmed-meshheading:11067902-Clone Cells,
pubmed-meshheading:11067902-Dose-Response Relationship, Immunologic,
pubmed-meshheading:11067902-Epitopes, T-Lymphocyte,
pubmed-meshheading:11067902-Immunotherapy, Adoptive,
pubmed-meshheading:11067902-Lymphocyte Activation,
pubmed-meshheading:11067902-Male,
pubmed-meshheading:11067902-Mice,
pubmed-meshheading:11067902-Mice, Inbred DBA,
pubmed-meshheading:11067902-Molecular Sequence Data,
pubmed-meshheading:11067902-Neoplasm Transplantation,
pubmed-meshheading:11067902-Oligopeptides,
pubmed-meshheading:11067902-Sarcoma, Experimental,
pubmed-meshheading:11067902-Th1 Cells,
pubmed-meshheading:11067902-Th2 Cells,
pubmed-meshheading:11067902-Tumor Cells, Cultured
|
| pubmed:year |
2000
|
| pubmed:articleTitle |
Th1 and Th2 cell clones to a poorly immunogenic tumor antigen initiate CD8+ T cell-dependent tumor eradication in vivo.
|
| pubmed:affiliation |
Department of Experimental Medicine, University of Perugia, Perugia, Italy.
|
| pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't
|